Immunocore Holdings plc IMCR
Set alert
As of Nov 2, 10:24 AM ET
- YTD
- -14.12%
- 1 year
- -9.91%
- Open
- 30.56
- Prev close
- 30.49
- Mkt cap
- 1.55B
- Vol
- 10.44K
- Avg vol
- 441.86K
- EPS
- -0.36
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 30.04
- High
- 30.83
- Forward P/E
- -40.06
- Beta
- 0.81
- Short ratio
- 17.07
- Inst. own
- 103.17%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 32.48
- 200-d avg
- 31.78
- 1y target
- 62.73
News
-
4 days ago benzinga.com
Immunocore To Present Phase 1/2 Trial Data Evaluating Brenetafusp Alone And In Combination With KIMMTRAK In HLA-A*02:01-Positive Patients With Metastatic Uveal Melanoma, At 2026 SITC Annual Meeting
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meetingClinical data for…
4 days ago globenewswire.com
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK ® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
-
6 days ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $100 price target.
2 weeks ago globenewswire.com
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes The Phase 1 trial will assess the…
4 weeks ago benzinga.com
Immunocore Hldgs Q2 2026 Earnings Call Transcript
Immunocore Hldgs (NASDAQ:IMCR) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide…
1 month ago zacks.com
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.
1 month ago seekingalpha.com
Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
-
1 month ago benzinga.com
Immunocore Holdings Announces Achievement Of Target Patient Enrollment In TEBE-AM Clinical Trial; Topline Overall Survival Data Expected As Early As End Of 2026
Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve
1 month ago globenewswire.com
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK ® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as…
2 months ago globenewswire.com
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the…
2 months ago defenseworld.net
Bank of America Corp DE Trims Stock Position in Immunocore Holdings PLC Sponsored ADR $IMCR
Bank of America Corp DE trimmed its position in Immunocore Holdings PLC Sponsored ADR (NASDAQ: IMCR) by 11.9% during the undefined quarter, according to its most recent filing with the Securities and…
2 months ago zacks.com
Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?
Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-2026 data could add further upside.
-
2 months ago benzinga.com
JP Morgan Reinstates Overweight on Immunocore Holdings, Announces $50 Price Target
JP Morgan analyst Jessica Fye reinstates Immunocore Holdings (NASDAQ:IMCR) with a Overweight and announces $50 price target.
2 months ago zacks.com
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum
Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.
2 months ago zacks.com
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?
Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.
2 months ago zacks.com
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss
Immunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocking headwind cloud the near-term outlook.
2 months ago zacks.com
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues
IMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.3% year over year on higher U.S. and international sales.
2 months ago zacks.com
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 77.9% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the…
2 months ago seekingalpha.com
Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call Transcript
Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Immunocore Q2 Earnings Call Highlights
Immunocore NASDAQ: IMCR reported continued growth for KIMMTRAK in the second quarter and first half of 2026, while advancing three late-stage melanoma trials and early-stage programs in oncology, HIV…
-
2 months ago benzinga.com
Immunocore Hldgs Q2 EPS $(0.02) Misses $0.02 Estimate, Sales $115.927M Beat $110.374M Estimate
Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.02 by 200 percent. This is a 90 percent increase over losses of $(0.20)…
2 months ago globenewswire.com
Immunocore reports second quarter financial results and provides a business update
Immunocore reports second quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in…
-
3 months ago benzinga.com
Mizuho Maintains Neutral on Immunocore Holdings, Raises Price Target to $35
Mizuho analyst Graig Suvannavejh maintains Immunocore Holdings (NASDAQ:IMCR) with a Neutral and raises the price target from $34 to $35.
3 months ago globenewswire.com
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 30 July 2026) Immunocore Holdings plc (Nasdaq:…
3 months ago zacks.com
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead
IMCR's Kimmtrak sales climbed 29% in 2025 on wider adoption, with pivotal 2026 trial results set to test its next expansion opportunity.
3 months ago zacks.com
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?
Kimmtrak's sales growth supports IMCR, but premium valuation and reliance on one product keep investors focused on upcoming pipeline catalysts.
3 months ago zacks.com
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak
Kimmtrak anchors IMCR today, but its broader T-cell receptor platform is targeting larger cancer, infectious disease and autoimmune markets.
-
6 months ago benzinga.com
Immunocore Hldgs Q1 EPS $0.25 Beats $(0.25) Estimate, Sales $106.677M Miss $107.731M Estimate
Immunocore Hldgs (NASDAQ:IMCR) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $(0.25) by 200 percent. This is a 150 percent increase over earnings of…
-
6 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $100 price target.
-
6 months ago benzinga.com
Reported Sunday, KIMMTRAK Five-Year Phase 3 Data Shows Doubled Survival Likelihood Versus Investigator's Choice With Median OS Of 21.6 Months Versus 16.9 Months In Metastatic Uveal Melanoma
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanomaOS benefit observed across key subgroups, including patients with high…
-
6 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $100 price target.
-
7 months ago benzinga.com
FDA Adverse Event Monitoring System Q4 2025 Flags Multiple Potential New Drug Safety Signals, Including Hypersensitivity, Hypogammaglobulinemia, Colitis, Aplastic Anemia And Rhabdomyolysis Under Evaluation
https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda
-
7 months ago benzinga.com
Immunocore Holdings To Present 5-Yr OS From KIMMTRAK Phase 3 Trial In Previously Untreated HLA-A*02:01 Positive Patients With Unresected Or mUM, At 2026 AACR Annual Meeting
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting(OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 17 March 2026)…
-
7 months ago benzinga.com
Jefferies Downgrades Immunocore Holdings to Hold, Lowers Price Target to $33
Jefferies analyst Clara Dong downgrades Immunocore Holdings (NASDAQ:IMCR) from Buy to Hold and lowers the price target from $48 to $33.
-
8 months ago benzinga.com
Earnings Scheduled For February 25, 2026
Earnings Scheduled For February 25, 2026
1 year ago benzinga.com
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday
-
1 year ago benzinga.com
Earnings Scheduled For February 26, 2025
Earnings Scheduled For February 26, 2025
-
2 years ago benzinga.com
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
-
2 years ago benzinga.com
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
-
2 years ago benzinga.com
Earnings Scheduled For February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.
-
2 years ago benzinga.com
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Applied Therapeutics, Inc.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 369 companies hit new 52-week lows.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
-
3 years ago benzinga.com
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
-
3 years ago benzinga.com
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2022
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 50 stocks hit new 52-week highs.